Quantitative aortography for assessing aortic regurgitation after transcatheter aortic valve implantation: results of the multicentre ASSESS-REGURGE Registry
EuroIntervention 15(5): 420-426
Article 2019 English
Authors
RM
Rodrigo Modolo
CC
Chun‐Chin Chang
HT
Hiroki Tateishi
Abstract
1 min read
Quantitative aortography using videodensitometry is a valuable tool for quantifying paravalvular regurgitation after TAVI, especially in the minimalist approach - without general anaesthesia. However, retrospective assessment of aortograms showed moderate feasibility of assessment. We sought to determine the prospective feasibility of quantitative aortography after a protocol of acquisition.This was a multicentre registry in Japan, Canada, the Netherlands and Germany including consecutive patients with Heart Team indication to undergo TAVI over a median period of 12 months. Operators performed final aortograms according to a pre-planned projection (either by CT or visually - Teng's rule). An independent core laboratory (Cardialysis) analysed all images for feasibility and for regurgitation assessment. From the four centres included in the present analysis, a total of 354 patients underwent TAVI following the acquisition protocol and all the aortograms were analysed by the core lab. The analyses were feasible in 95.5% (95% confidence interval [CI]: 93.2% to 97.5%) of the cases. This rate of analysable assessment was significantly higher than the feasibility in previous validation studies, such as in the RESPOND population (95.5% vs. 57.5%, p<0.0001). No differences were observed among different planning strategies (CT 96.5% vs. Teng's rule 93%, p=0.159; or Circle 98.5% vs. 3mensio 95.8% vs. Teng's rule 93%, p=0.247).ASSESS-REGURGE showed a high feasibility of assessment of regurgitation with quantitative aortography with protocoled acquisition. This may be of great importance for quantifying regurgitation in TAVI procedures (optimisation, guidance of post-dilatation), and in future clinical trials, in order to address sealing features of novel devices for TAVI objectively. ClinicalTrials.gov Identifier: NCT03644784.
Hiroki Tateishi, Carlos M. Campos, Mohammad Abdelghani, Rogério Sarmento Leite, José Armando Mangione, Lizet Bary, Osama Soliman, Ernest Spitzer, Marco Perin, Yoshinobu Onuma, Patrick W. Serruys, Pedro A. Lemos, Fábio Sândoli de Brito
Andreas Rück, Won‐Keun Kim, Hideyuki Kawashima, Mahmoud Abdelshafy, Ahmed Elkoumy, Hesham Elzomor, Rutao Wang, Christopher Meduri, Dinos Verouhis, Nawzad Saleh, Yoshinobu Onuma, Darren Mylotte, Patrick W. Serruys, Osama Soliman
Hideyuki Kawashima, Rutao Wang, Darren Mylotte, Dariusz Jagielak, Frederico De Marco, Alfonso Ielasi, Yoshinobu Onuma, Peter den Heijer, Christian Juhl Terkelsen, William Wijns, Patrick W. Serruys, Osama Soliman
Rodrigo Modolo, Martijn van Mourik, Abdelhak el Bouziani, Hideyuki Kawashima, Liesbeth Rosseel, Mohammad Abdelghani, Jean-Paul Aben, Tristan Slots, Cherif Sahyoun, Jan Baan, José P.S. Henriques, Karel T. Koch, Marije M. Vis, Osama Soliman, Yoshinobu Onuma, Joanna J. Wykrzykowska, Robbert de Winter, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.